1. pregnancy or breast feeding 2. autoimmune thrombocytopenia, myelodysplastic syndromes with \> 20% marrow blast cells 3. history or presence of hypersensitivity or idiosyncratic reaction to molgramostim (e.g. leucomax®) or to related compounds (e.g. leukine®) 4. patient not able to use nebulizer device as well as immediately foreseeable mechanical ventilation of the patient 5. simultaneous participation in another clinical trial with an experimental treatment

1. pregnancy or breast feeding 2. autoimmune thrombocytopenia, myelodysplastic syndromes with \> 20% marrow blast cells 3. history or presence of hypersensitivity or idiosyncratic reaction to molgramostim (e.g. leucomax®) or to related compounds (e.g. leukine®) 4. patient not able to use nebulizer device as well as immediately foreseeable mechanical ventilation of the patient 5. simultaneous participation in another clinical trial with an experimental treatment

pregnancy or breast feeding autoimmune thrombocytopenia, myelodysplastic syndromes with > 20% marrow blast cells history or presence of hypersensitivity or idiosyncratic reaction to molgramostim (e.g. leucomax®) or to related compounds (e.g. leukine®) patient not able to use nebulizer device as well as immediately foreseeable mechanical ventilation of the patient simultaneous participation in another clinical trial with an experimental treatment

pregnancy or breast feeding autoimmune thrombocytopenia, myelodysplastic syndromes with > 20% marrow blast cells history or presence of hypersensitivity or idiosyncratic reaction to molgramostim (e.g. leucomax®) or to related compounds (e.g. leukine®) patient not able to use nebulizer device as well as immediately foreseeable mechanical ventilation of the patient simultaneous participation in another clinical trial with an experimental treatment

1. pregnancy or breast feeding 2. autoimmune thrombocytopenia, myelodysplastic syndromes with > 20% marrow blast cells 3. history or presence of hypersensitivity or idiosyncratic reaction to molgramostim (e.g. leucomax®) or to related compounds (e.g. leukine®) 4. patient not able to use nebulizer device as well as immediately foreseeable mechanical ventilation of the patient 5. simultaneous participation in another clinical trial with an experimental treatment

1. pregnancy or breast feeding 2. autoimmune thrombocytopenia, myelodysplastic syndromes with > 20% marrow blast cells 3. history or presence of hypersensitivity or idiosyncratic reaction to molgramostim (e.g. leucomax®) or to related compounds (e.g. leukine®) 4. patient not able to use nebulizer device as well as immediately foreseeable mechanical ventilation of the patient 5. simultaneous participation in another clinical trial with an experimental treatment

1. pregnancy or breast feeding 2. autoimmune thrombocytopenia, myelodysplastic syndromes with > 20% marrow blast cells 3. history or presence of hypersensitivity or idiosyncratic reaction to molgramostim (e.g. leucomax®) or to related compounds (e.g. leukine®) 4. patient not able to use nebulizer device 5. simultaneous participation in another clinical trial with an experimental treatment

1. pregnancy or breast feeding 2. autoimmune thrombocytopenia, myelodysplastic syndromes with > 20% marrow blast cells 3. history or presence of hypersensitivity or idiosyncratic reaction to molgramostim (e.g. leucomax®) or to related compounds (e.g. leukine®) 4. patient not able to use nebulizer device 5. simultaneous participation in another clinical trial with an experimental treatment